{
    "nctId": "NCT00305448",
    "briefTitle": "A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg",
    "officialTitle": "Phase II Study to Evaluate the Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg in Postmenopausal Women With ER +ve Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Breast Cancer, Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 143,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor\n* Requiring hormonal treatment\n* Postmenopausal women defined as a woman who has stopped having menstrual periods\n\nExclusion Criteria:\n\n* Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced breast cancer\n* Treatment with more than one previous regimen of endocrine therapy for advanced breast cancer\n* An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}